BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Jan. 24, 2002
View Archived Issues
EntreMed, Allergan Collaborate On Ophthalmic Uses Of Panzem
Allergan Inc. struck a five-year deal potentially worth more than $40 million with EntreMed Inc. to develop and commercialize the latter’s angiogenic inhibitor, Panzem, for ophthalmolic uses.
Read More
Xenerex Enters Antibody Deal With Schering-Plough’s DNAX
Read More
3-D Structure Of Deadly Bacillus Anthracis Edema Factor Protein Reveals Drug-Finding Weak Spot
Read More
NeurogesX Raises $23M To Develop Products For Pain
Read More
Other News To Note
Read More
U.S. Patent Disclosures
Read More